EMA Recommends Caution For Pfizer's Xeljanz
The Agency Has Also Issued Restrictions For Sanofi's Lemtrada
The European Medicines Agency's drug safety committee has concluded that Pfizer's Xeljanz could increase the risk of blood clots in patients who are already at high risk. The committee has also recommended restrictions on the use of Sanofi's multiple sclerosis drug, Lemtrada.
